New FDA head’s Planned Parenthood past prompts concerns from anti-abortion lobby
Kyle Diamantas, the new acting commissioner of the FDA, is under scrutiny from the anti-abortion lobby due to his previous work with Planned Parenthood. Despite this, some advocates express cautious support, emphasizing that his current actions will be more telling than his past. The controversy highlights ongoing tensions surrounding abortion-related drug regulations.
- ▪Kyle Diamantas was previously retained as corporate counsel for Planned Parenthood.
- ▪Anti-abortion activists have raised concerns about his past involvement with the organization.
- ▪Some advocates believe Diamantas should be judged by his current actions rather than his history.
Opening excerpt (first ~120 words) tap to expand
The new acting commissioner of the Food and Drug Administration is facing pressure from the anti-abortion lobby after it emerged that Kyle Diamantas had previously been retained as corporate counsel for Planned Parenthood, despite strong support from the Trump administration and top leaders in the movement. Diamantas, 38, was previously the director of the Human Foods Program at the FDA and was selected to work as acting commissioner after President Donald Trump’s first FDA commissioner, Marty Makary, abruptly resigned this week. Almost immediately after his appointment was announced, anti-abortion activists began to peer into his past, finding at least one eyebrow-raising instance in his professional career for what conservatives view as an unsavory former client.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Washington Examiner.
Discussion
0 commentsMore from Washington Examiner
